Kenneth Frazier, the CEO of drug manufacturer Merck, says the company will seek approval for a drug that reverses anesthesia after surgery in 2012, according to a Bloomberg Businessweek report.
Mr. Frazier has had a rocky first year with the company. Last Jan. 2011, after he took the helm, Merck unexpectedly ended a late-stage study of a blood thinner due to bleeding risks. Merck's return to shareholders dropped to the lowest in the industry after problems delayed other drugs.
Mr. Frazier said the company will seek approval for Bridion, a drug for reversing anesthesia that is approved in many other countries but was rejected in the U.S. in 2008.
Related Articles on Anesthesia:
Anesthesiologist Who Treated JFK in Dallas ER Dies at 79
Surgery With Anesthesia May Prompt Memory Loss Cognitive Decline
Minneapolis Hospital Mistakenly Gives Surgery Patient Paralyzing Anesthetic
Mr. Frazier has had a rocky first year with the company. Last Jan. 2011, after he took the helm, Merck unexpectedly ended a late-stage study of a blood thinner due to bleeding risks. Merck's return to shareholders dropped to the lowest in the industry after problems delayed other drugs.
Mr. Frazier said the company will seek approval for Bridion, a drug for reversing anesthesia that is approved in many other countries but was rejected in the U.S. in 2008.
Related Articles on Anesthesia:
Anesthesiologist Who Treated JFK in Dallas ER Dies at 79
Surgery With Anesthesia May Prompt Memory Loss Cognitive Decline
Minneapolis Hospital Mistakenly Gives Surgery Patient Paralyzing Anesthetic